BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has received a consensus rating of “Moderate Buy” from the seventeen brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $133.7333.

A number of brokerages have recently issued reports on BNTX. Morgan Stanley cut their target price on shares of BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 10th. Truist Financial set a $155.00 price target on BioNTech in a research note on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective on the stock. in a research note on Monday, February 2nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 target price on shares of BioNTech in a report on Wednesday, March 11th.

BioNTech Trading Down 0.7%

NASDAQ BNTX opened at $90.54 on Tuesday. The company has a market capitalization of $21.73 billion, a price-to-earnings ratio of -17.28 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The company’s fifty day moving average price is $106.30 and its two-hundred day moving average price is $102.46.

Hedge Funds Weigh In On BioNTech

Several large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in BioNTech by 95.9% during the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of BioNTech in the 1st quarter worth about $167,000. Envestnet Asset Management Inc. lifted its position in shares of BioNTech by 20.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 10,570 shares of the company’s stock worth $1,125,000 after buying an additional 1,808 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of BioNTech by 1,176.8% in the 2nd quarter. Allworth Financial LP now owns 1,213 shares of the company’s stock valued at $129,000 after buying an additional 1,118 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in shares of BioNTech by 80.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,746 shares of the company’s stock valued at $186,000 after buying an additional 779 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.